Pharmacokinetic Study of Palifermin in Subjects Receiving Radiation Therapy and Chemotherapy Followed by Blood Stem Cell Support

NCT00070616 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Leukemia
Lymphoma
Myeloma

Interventions

DRUG: Palifermin 6 x 60 μg/kg/day
DRUG: Palifermin 2 x 180 μg/kg/day
RADIATION: radiotherapy
DRUG: Chemotherapy

Sponsor

Swedish Orphan Biovitrum

Collaborators

[object Object]